Close
Novotech
Jabsco PureFlo 21 Single Use

Drug Research

Meaningful Investment To Enable Tirzepatide API Production

It is well to be noted that a fresh $5.3 billion investment for pharma giant Eli Lilly and Company’s manufacturing site based in Lebanon, Indiana, US has gone on to raise the organization’s total investment in the country from...

Germany – Taking Right Steps Towards Pharma Drugs Reshoring

As part of its endeavors to throttle the pharma sector domestically, the German government has gone ahead with the adoption of a strategy paper in December 2023, which identified three major areas that need to be strengthened. The objectives include...

Green Chemistry Innovations Key To Pharma Solvent Sector

The pharmaceutical solvents sector has gone on to secure a valuation worth $3.9 billion in 2023 and is all set to scale the $6 billion mark by 2033 with a CAGR of 4.6% throughout the forecast period. Let us have...

Inside Out of The Pharmaceutical Fine Chemicals Segment

The pharmaceutical fine chemicals market is all set to showcase significant growth, with an increase from $136 billion in 2024 to an expected $233 billion by 2031. This surge is going to be driven by a CAGR of 8%...

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Roche announced that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens...

FDA Grants Roche Tina-qant Lp Assay Breakthrough Device Designation – a key marker for hereditary cardiovascular risk

Roche announced  that the Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. FDA  to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development. Lp(a) is emerging as an important, yet under-recognised,...

Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines

Eli Lilly and Company announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion. This expansion will...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »